Cobus Loots, CEO of Pan African Resources, on delivering sector-leading returns for shareholders. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAvacta Group Share News (AVCT)

Share Price Information for Avacta Group (AVCT)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 42.00
Bid: 41.50
Ask: 42.50
Change: 1.00 (2.44%)
Spread: 1.00 (2.41%)
Open: 42.25
High: 42.50
Low: 41.00
Prev. Close: 41.00
AVCT Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

EARNINGS AND TRADING: Harland & Wolff wins major Falklands contract

Tue, 05th Mar 2024 17:09

(Alliance News) - The following is a round-up of earnings and trading updates by London-listed companies, issued on Tuesday and not separately reported by Alliance News:

----------

STV Group PLC - Glasgow-based broadcaster - Revenue grows 22% to GBP168.4 million in 2023 from GBP137.8 million a year prior. Total advertising revenue drops 12% to GBP97.3 million from GBP110.0 million. Adjusted pretax profit was GBP9.5 million for the year, down from GBP24.1 million in 2022. STV's dividend was flat for the year at 11.3p per share, after a final dividend of 7.4p. STV has secured GBP87 million in future revenue as at March, GBP30 million a head of the same time a year ago, and the company is encouraged by the "resilience" shown by the advertising market in the year so far. Chief Executive Officer Simon Pitts says: "Our overall financial performance was impacted by weak linear advertising and cost inflation, as expected and related to the challenging UK macro environment, although the start of 2024 has been more encouraging."

----------

Avacta Group PLC- Wetherby, England-based life sciences company specialising in oncology treatments - Set to issue 10.9 million new shares at a price of 50p each following its February retail offer. This remains subject to shareholder approval at the company's annual general meeting on March 18. The REX offer received total applications in excess of the GBP6.8 million limit. The company decided to limit the offer to existing Avacta retail shareholders, and expects a total of GBP5.4 million to be raised from the offer. The company says the proceeds will be used to support the continued clinical development of AVA6000, the company's signature treatment capable of targeting a chemotherapy to the tumour while sparing healthy tissue.

----------

Argo Blockchain PLC - London-based cryptocurrency miner - Enters into agreement for sale of Mirabel, Quebec data centre for a total consideration of USD6.1 million. The proceeds from the sale will be used to repay the facility's outstanding mortgage in full, and the remainder used to pay debts owned to Galaxy Digital Holdings Ltd, an asset manager and trade advisor specialising in digital assets. As of February 29, the Galaxy debt stands at USD14.0 million. The company is in the process of moving mining machines out of the Mirabel facility, and expects the transaction to close by the end of March.

----------

Harland & Wolff Group Holdings PLC - London-based fabrication company, which serves the maritime and offshore industries - Says it has been awarded preferred bidder status for the Falkland Islands Port Replacement Project by the Falkland Islands Government. H&W believes this contract could generate total revenues between GBP100 and GBP120 million over a two-year period, with works on the project expected to commence this year.

----------

Oxford BioMedica PLC - Oxfordshire, England-based gene and cell-therapy company - Updates annual guidance, expecting 2024 revenue of around GBP126 million to GBP134 million. Guidance for the 2023 full-year remains unchanged, with group revenue expected to be around GBP90 million. The group is expecting a loss before interest, tax, depreciation and amortisation for 2023, but is targeting break-even operating Ebitda by the end of 2024.

----------

By Hugh Cameron, Alliance News reporter

Comments and questions to newsroom@alliancenews.com

Copyright 2024 Alliance News Ltd. All Rights Reserved.

More News
8 Feb 2021 09:37

Avacta Signs Agreement With Mologic For AffiDX Covid-19 Antigen Test

Avacta Signs Agreement With Mologic For AffiDX Covid-19 Antigen Test

Read more
1 Feb 2021 14:37

TRADING UPDATES: Asiamet Hits Back At Shareholder; Hardide Raises Cash

TRADING UPDATES: Asiamet Hits Back At Shareholder; Hardide Raises Cash

Read more
1 Feb 2021 09:25

Avacta joint venture with Daewoong raises $7.3m in series A funding

(Sharecast News) - Biotherapeutics developer Avacta Group announced on Monday that its joint venture with Daewoong Pharmaceutical, AffyXell Therapeutics, has closed a series A venture capital investment of $7.3m (£5.32m) to further develop its pipeline of next generation cell and gene therapies.

Read more
28 Jan 2021 14:42

IN BRIEF: Avacta Lands Deal With Bruker To Assess SARS-CoV-2 Test

IN BRIEF: Avacta Lands Deal With Bruker To Assess SARS-CoV-2 Test

Read more
7 Jan 2021 13:51

IN BRIEF: Avacta Group Enters License Agreement With Point Biopharma

IN BRIEF: Avacta Group Enters License Agreement With Point Biopharma

Read more
7 Jan 2021 08:58

Avacta enters licence agreement with Point Biopharma

(Sharecast News) - Cancer therapy and diagnostics developer Avacta Group has entered into a licence agreement with Point Biopharma, it announced on Thursday, to provide access to its 'preCISION' technology for the development of tumour-activated radiopharmaceuticals.

Read more
23 Dec 2020 19:50

UK TRADING UPDATE SUMMARY: Polarean And Amryt Get US FDA Boost

UK TRADING UPDATE SUMMARY: Polarean And Amryt Get US FDA Boost

Read more
23 Dec 2020 08:56

Avacta submits clinical trial application for 'AVA6000' prodrug

(Sharecast News) - Cancer therapy developer Avacta Group has submitted a clinical trial application in the UK for a phase 1 first-in-human open label dose-escalation and expansion study of its lead 'preCISION' prodrug, 'AVA6000', in patients with locally-advanced or metastatic selected solid tumours, it announced on Wednesday.

Read more
21 Dec 2020 18:10

UK TRADING UPDATE SUMMARY: Novacyt Tests Can Spot New Virus Strain

UK TRADING UPDATE SUMMARY: Novacyt Tests Can Spot New Virus Strain

Read more
21 Dec 2020 09:49

Avacta enters 'Affimer' licensing deal with Astrea Bioseparations

(Sharecast News) - Cancer therapies and diagnostics developer Avacta Group has entered into a licensing agreement with Astrea Bioseparations, it announced on Monday, for the use of the 'Affimer' platform in affinity purification applications.

Read more
23 Nov 2020 15:20

Avacta reports 'significant progress' on Covid-19 test

(Sharecast News) - Cancer therapies and diagnostics developer Avacta Group announced "significant progress" in the development of a scalable manufacturing process for a lateral flow SARS-CoV-2 antigen test being carried out with BBI Solutions on Monday.

Read more
22 Oct 2020 15:53

UK DIRECTOR DEALINGS SUMMARY: Dunkerton Buys More Superdry Shares

UK DIRECTOR DEALINGS SUMMARY: Dunkerton Buys More Superdry Shares

Read more
1 Oct 2020 06:40

IN BRIEF: Avacta Stock Continues Rise After Launch Of SARS-CoV-2 Test

IN BRIEF: Avacta Stock Continues Rise After Launch Of SARS-CoV-2 Test

Read more
24 Sep 2020 15:43

UK's Integumen unveils prototype COVID-19 breath test

LONDON, Sept 24 (Reuters) - Integumen, a British company that developed a system to detect the COVID-19 virus in waste water, said the same technology could be deployed in a personalised breath test that could become an effective tool in fighting...

Read more
21 Sep 2020 16:08

UK Earnings, Trading Statements Calendar - Next 7 Days

UK Earnings, Trading Statements Calendar - Next 7 Days

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.